OpenAI acquires Orchestra Bio to bring AI agents into drug development

OpenAI has bought Orchestra Bio, a startup that makes AI agents for drug development teams. The company said the startup’s staff and technology are moving into its Rosalind life sciences unit, where OpenAI has been building tools for biology and drug discovery.

The pitch is straightforward: drug programs are slow, fragmented and expensive to manage. OpenAI says getting a medicine through U.S. regulatory approval takes 10 to 15 years on average, and work is split across departments and outside partners that often use systems that don’t talk to each other. Orchestra’s software is meant to keep studies on track, monitor programs and help with the kind of operational snags that can derail timelines.

TechCrunch said the tools can also track finances and sort out clinical trial scheduling problems. In OpenAI’s example, if a manufacturing batch failed and threatened to delay a trial, the system would map out what gets hit and suggest responses. But humans still make the final decision, which is probably the least surprising part of the whole announcement.

OpenAI said scientists should be able to use the combined tools to make discoveries and manage the work needed to turn them into treatments. It did not disclose the terms of the deal or give a timeline for when Orchestra’s agents will appear in its products.

Rosalind itself launched in April as a reasoning model for biology and drug discovery research, and eligible organizations have been able to use it outside research preview since September through a trusted-access program. Rosalind Workbench connects the model to scientific tools and data. Novo Nordisk and Moderna are already working with OpenAI on Rosalind, and this is not OpenAI’s first health care move this year: Medical records company Torch Health joined in January to build out ChatGPT Health. OpenAI’s purchase lands in a market where Anthropic bought AI biotech startup Coefficient Bio in April for about $400 million.